Published in Vaccine Weekly, September 6th, 2006
According to the review from Norway, "Multiple myeloma (MM) remains a difficult-to-cure cancer and less than 20% of patients achieve long-term survival irrespective of the treatment delivered, including high-dose chemotherapy. Thus, new treatment modalities are urgently needed."
Bjarne Bogen and colleagues at the University of Oslo wrote, "Myeloma cells produce a monoclonal immunoglobulin (Ig), which is a truly tumor-specific antigen. The tumor-specific antigenic determinants are localized in the variable regions of the monoclonal Ig and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly